In addition to Quincy Health LLC extending its debt maturities to January 2028, its full-year 2024 performance was in line with our expectations and it met its asset-based lending (ABL) facility covenant requirement. We raised our ratings on Quincy, including the issuer credit rating, to ?CCC? from ?CCC-. The outlook is negative. However, given continued tight liquidity and slim covenant headroom under its ABL facility, we believe there remains substantial risk of a payment default or amendments that we may view as distressed. We also raised our issue-level rating on the company's term loan to 'CCC' from 'CCC-'. Our recovery rating remains '4' (from our last estimate) and reflects our expectation of average (30%-50%; rounded estimate: 35%) recovery in the